M. Ravic

1.2k citations

36 papers · 973 indexed · h-index 14

Impact in

Gastroenterology top 5%
- Gastroesophageal reflux and treatments
Oncology top 10%
- CAR-T cell therapy research

Papers in ⓘ

Oncology 14
- Drug Transport and Resistance Mechanisms 6
- CAR-T cell therapy research 3
Pharmacology 8
- Pharmacogenetics and Drug Metabolism 8
- Antibiotics Pharmacokinetics and Efficacy 4

Co-authors: Philippe Jornod (1 shared paper)D. Pantoflickova (1 shared paper)P. Fumoleau (8 shared papers)Gian Dorta (1 shared paper)A. L. Blum (1 shared paper)Jan H.M. Schellens (7 shared papers)Dennis A. Eichenauer (5 shared papers)Achim Rothe (5 shared papers)
Journals: Journal of Clinical Oncology (5 papers)Blood (4 papers)British Journal of Clinical Pharmacology (3 papers)Alimentary Pharmacology & Therapeutics (2 papers)Anti-Cancer Drugs (2 papers)
Partner nations: United Kingdom Netherlands Germany

In The Last Decade

M. Ravic

35 papers receiving 930 citations

Peers

Countries citing papers authored by M. Ravic

Since Specialization

Citations

This map shows the geographic impact of M. Ravic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ravic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ravic more than expected).

Fields of papers citing papers by M. Ravic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Ravic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ravic. The network helps show where M. Ravic may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Ravic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Ravic Line = papers co-authored together M. Ravic links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Blood ·Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, M. Ravic, Stefan Knackmuss, Jens‐Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert	2015	253
2	Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors Alimentary Pharmacology & Therapeutics ·D. Pantoflickova, Gian Dorta, M. Ravic, Philippe Jornod, A. L. Blum	2003	116
3	5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent Clinical Cancer Research ·Mark J. McKeage, Peter C.C. Fong, Mark Jeffery, Bruce C. Baguley, Phil Kestell, M. Ravic, Michael B. Jameson	2006	86
4	Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer Journal of Clinical Oncology ·Éric Raymond, W.W. ten Bokkel Huinink, Julien Taı̈eb, Jos H. Beijnen, Sandrine Faivre, J. Wanders, M. Ravic, P. Fumoleau, Jean‐Pierre Armand, Jan H.M. Schellens	2002	48
5	Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam Investigational New Drugs ·Charlotte van Kesteren, Anthe S. Zandvliet, Mats O. Karlsson, Ron A. A. Mathôt, Cornelis J. A. Punt, Jean‐Pierre Armand, Éric Raymond, Alwin D. R. Huitema, Christian Dittrich, Herlinde Dumez, Henri Roché, Jean‐Pierre Droz, M. Ravic, S. Murray Yule, J. Wanders, Jos H. Beijnen, P. Fumoleau, Jan H.M. Schellens	2005	47
6	Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG) Annals of Oncology ·Cornelis J. A. Punt, P. Fumoleau, Baudouin van de Walle, M.N. Faber, M. Ravic, Mario Campone	2001	46
7	Phase II study of E7070 in patients with metastatic melanoma Annals of Oncology ·J F Smyth, S. Aamdal, Ahmad Awada, Christian Dittrich, Francesco Caponigro, Patrick Schöffski, Martin Gore, Thierry Lesimple, N. Djurasinovic, B. Barón, M. Ravic, P. Fumoleau, C. J. A. Punt	2004	46
8	Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG) European Journal of Cancer ·C. Terret, Sylvie Zanetta, Henri Roché, Jan H.M. Schellens, M.N. Faber, J. Wanders, M. Ravic, Jean‐Pierre Droz	2003	41
9	Safety and efficacy of 7‐day rabeprazole‐ and omeprazole‐based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease Alimentary Pharmacology & Therapeutics ·Christopher J. Hawkey, John C. Atherton, H.‐C. Treichel, Bjarni Þjóðleifsson, M. Ravic	2003	36
10	Population Pharmacokinetics of the Novel Anticancer Agent E7070 During Four Phase I Studies: Model Building and Validation Journal of Clinical Oncology ·Ch. van Kesteren, Ron A. A. Mathôt, Éric Raymond, Jean‐Pierre Armand, Ch. Dittrich, Herlinde Dumez, Henri Roché, Jean‐Pierre Droz, Cornelis J. A. Punt, M. Ravic, J. Wanders, Jos H. Beijnen, P. Fumoleau, Jan H.M. Schellens	2002	36
11	Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer The Journal of Urology ·J. Falke, Rianne J.M. Lammers, H.C. Arentsen, M. Ravic, Raffaella Pozzi, Erik B. Cornel, H. Vergunst, Theo M. de Reijke, J. Alfred Witjes	2012	34
12	Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment Scandinavian Journal of Gastroenterology ·Peter Bytzer, Anna Morocutti, Peter Kennerly, M. Ravic, Neil Miller, ON BEHALF OF THE ROSE TRIAL INVESTI	2006	18
13	Renal and General Tolerability of Repeated Doses of Nimesulide in Normal Subjects Drugs ·SJ Warrington, M. Ravic, ABS Dawnay	1993	17
14	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer Clinical Genitourinary Cancer ·Tom J.H. Arends, Rianne J.M. Lammers, J. Falke, Antoine G. van der Heijden, Irene Rustighini, Raffaella Pozzi, M. Ravic, A. Eisenhardt, H. Vergunst, J. Alfred Witjes	2014	15
15	An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients Anti-Cancer Drugs ·H.J.G.D. van den Bongard, Dick Pluim, Hilde Rosing, Lianda G. A. H. Nan‐Offeringa, Margaret Schot, M. Ravic, Jan H.M. Schellens, Jos H. Beijnen	2002	13
16	A Study of the Interaction between Lornoxicam and Warfarin in Healthy Volunteers Human & Experimental Toxicology ·M. Ravic, A. E. Johnston, Paul Turner, H. Ferber	1990	13
17	Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation. PubMed ·Steve Warrington, Yuet Lewis, ABS Dawnay, A. E. Johnston, Iren B. Kovács, Sarah E Lamb, M. Ravic	1990	12
18	Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. PubMed ·M. Ravic, A. E. Johnston, P Turner	1990	11
19	In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood Anti-Cancer Drugs ·H.J.G.D. van den Bongard, Dick Pluim, Robert C.A.M. van Waardenburg, M. Ravic, Jos H. Beijnen, J. Schellens	2003	9
20	Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N‐(3‐chloro‐7‐indolyl)‐1,4‐benzenedisulphonamide) British Journal of Clinical Pharmacology ·Charlotte van Kesteren, Ron A. A. Mathôt, Éric Raymond, Jean‐Pierre Armand, P. Fumoleau, Cornelis J. A. Punt, M. Ravic, J. Wanders, Jos H. Beijnen, Jan H.M. Schellens	2002	8

About M. Ravic

M. Ravic is a scholar working on Oncology, Pharmacology, Surgery, Pharmacology and Molecular Biology, having authored 36 papers that have together received 973 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (8 papers), Drug Transport and Resistance Mechanisms (6 papers), Helicobacter pylori-related gastroenterology studies (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Cancer therapeutics and mechanisms (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Gastroenterology (151 citations), Oncology (398 citations), Pharmacology (106 citations), Immunology (198 citations) and Pathology and Forensic Medicine (114 citations). M. Ravic has collaborated with scholars based in United Kingdom, Netherlands and Germany. Frequent co-authors include Philippe Jornod, D. Pantoflickova, P. Fumoleau, Gian Dorta, A. L. Blum, Jan H.M. Schellens, Dennis A. Eichenauer, Achim Rothe, J. Wanders and Katrin S. Reiners. Their work appears in journals such as Journal of Clinical Oncology, Blood, British Journal of Clinical Pharmacology, Alimentary Pharmacology & Therapeutics and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact